According to the top vaccine researcher at the US Walter Reed Army Institute of Research, scientists at the institute expect to know in the next few days if there's a concern that the COVID-19 vaccines might not work against a mutated variant of the virus that's rapidly spreading in parts of England, CNN reported on Monday.
Dr Nelson Michael, director of the Centre for Infectious Diseases Research at the Walter Reed Army Institute of Research, said that the Walter Reed scientists still expect the COVID-19 vaccine will be effective against this new virus variant.
Reportedly, on 17 December 2020, the Walter Reed team started examining genetic sequences of the new UK variant posted online by British researchers, with a computer analysis being done as a first step.
Michael said: "The computer analysis will allow us to gauge how much concern we should have", adding, "Other teams around the world are doing this analysis, too."
If the computer analysis shows there's a concern, then studies would need to be done in the laboratory and in animals to more definitively determine if the vaccine will work on this variant, CNN added.
Eli Lilly's Omvoh receives US FDA approval
Axcynsis Therapeutics' IND for AT03-65 receives US FDA approval
Innovent Biologics' IBI343 receives Breakthrough Therapy Designation in China
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Johnson & Johnson submits New Drug Application for TAR-200 to treat bladder cancer
GenSight Biologics reports positive five-year results for LUMEVOQ gene therapy in LHON Patients
Futura Medical plc reports positive results from WSD4000 Home User Study
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Sen-Jam Pharmaceutical receives ethics approval for Australian clinical trial of SJP-001
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
Kelker Pharma introduces NUTRILINQ for patients using weight loss drugs
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
BioArctic reports FDA acceptance of BLA for for subcutaneous maintenance dosing of Leqembi
Revvity and Element Biosciences partner to enhance neonatal sequencing for IVD testing